Alnylam is developing novel RNA interference- (RNAi-) based therapeutics that use double-stranded RNA to prevent the expression of specific genes. The company has several programmes in clinical development. It was formed from the merger of Ribopharma, the first RNAi-therapeutics company, which was founded with funding from Abingworth, and Alnylam. Alnylam went public in May 2004.